Nocturnal enuresis in children — Frequently asked questions (FAQ)
1) What does this algorithm cover?
This algorithm guides the approach to nocturnal enuresis in children, from the initial assessment — clinical history, physical examination, urinalysis and bladder diary — to the identification of warning signs. It structures clinical decision-making to distinguish monosymptomatic from non-monosymptomatic enuresis, and primary from secondary enuresis, and defines a stepwise treatment pathway with behavioural measures and first-line therapies, including the enuresis alarm and desmopressin, as well as reassessment and referral criteria.
2) From what age is nocturnal enuresis considered?
Nocturnal enuresis is defined as involuntary urine loss during sleep in children aged ≥ 5 years. Before this age, it is usually considered a developmental variant, and reassurance and general measures should be prioritised rather than specific therapeutic intervention.
3) What is the difference between monosymptomatic and non-monosymptomatic enuresis?
Monosymptomatic enuresis occurs without daytime urinary symptoms. Non-monosymptomatic enuresis is associated with lower urinary tract symptoms during the day, such as urgency, frequency, incontinence, dysuria or weak stream, and/or comorbidities such as constipation. In these cases, daytime dysfunction and/or constipation should be treated first, before starting enuresis-specific therapy.
4) What do primary and secondary enuresis mean?
Primary enuresis occurs when there has never been a sustained period of night-time bladder control. Secondary enuresis refers to recurrence after a period of continence of at least 6 months. In secondary enuresis, it is essential to look for reversible causes, such as constipation, urinary tract infection, psychosocial stress or sleep disorders, and to exclude warning signs; referral may be justified depending on the clinical context.
5) What initial assessment should be performed in primary care?
Assessment should include a targeted history, covering frequency and pattern of wet nights, family history, fluid intake, sleep/snoring and comorbidities, as well as screening for daytime urinary symptoms and constipation. A bladder diary, ideally including fluid intake, and urinalysis are recommended to exclude urinary tract infection and metabolic causes. The physical examination should include abdominal assessment and basic lumbosacral/neurological inspection to screen for underlying pathology.
6) What are the main warning signs or red flags?
Targeted investigation and/or referral should be considered in the presence of significant daytime incontinence, weak stream or retention, recurrent urinary tract infection, fever, haematuria or pain, marked polyuria/polydipsia, neurological signs or lumbosacral cutaneous signs, such as an atypical dimple or hair tuft, suspected urological malformation, unexplained faltering growth, suspected moderate to severe obstructive sleep apnoea, or secondary enuresis with relevant medical suspicion or significant psychosocial distress.
7) Are behavioural measures always necessary?
Yes. Supportive measures are recommended for all children: regular voiding and voiding before bedtime, adequate daytime hydration with reduction of fluids in the hours before sleep, avoidance of caffeinated drinks late in the day, positive reinforcement and involvement of the child. Constipation should be identified and treated when present, and sleep hygiene should be optimised. These measures may be sufficient in mild cases.
8) Is scheduled waking the same as an enuresis alarm?
No. Scheduled waking consists of waking the child at fixed times to urinate and is not recommended as the main therapeutic strategy, because it does not promote lasting benefit. The enuresis alarm is activated at the onset of urination, promotes conditioning and improves the ability to wake in response to bladder signals. It is considered a first-line treatment with a higher likelihood of sustained response.
9) When should an enuresis alarm be chosen as first-line treatment?
The alarm is preferable when the child and family are motivated and available for a treatment that requires adherence and follow-up. In general, it has a lower relapse rate and a higher likelihood of sustained cure. Technique and adherence should be reviewed after 2–3 weeks, and efficacy assessed after 6–8 weeks, continuing until a consistent pattern of dry nights and a maintenance period are achieved.
10) When should desmopressin be chosen?
Desmopressin is useful when a rapid effect is desired, such as for holidays or camps, and in children with suspected nocturnal polyuria. It is essential to reinforce night-time fluid restriction to reduce the risk of hyponatraemia. The intranasal formulation should be avoided because of a higher risk of adverse effects.
11) What is the usual desmopressin dosing regimen?
For nocturnal enuresis, treatment may be started with 0.2 mg orally at bedtime. If the response is insufficient and adherence is adequate, the dose may be increased to 0.4 mg. Response should be assessed after 2–4 weeks. If effective, treatment is usually continued for around 3 months, followed by an attempt at gradual reduction in dose and/or frequency, with clinical reassessment.
12) What should be done if there is no response to treatment?
Adherence and correct use should be confirmed, including alarm technique and desmopressin safety rules, and comorbidities should be reassessed, including constipation, subtle lower urinary tract symptoms, obstructive sleep apnoea and psychosocial factors. The strategy can then be changed, switching between alarm and desmopressin. If resistance persists, combination therapy, such as desmopressin plus an anticholinergic in selected cases, and/or referral to Paediatrics or Paediatric Urology may be considered.
